TY - JOUR
T1 - Should new antimalarial drugs be subsidized?
AU - Laxminarayan, Ramanan
AU - Parry, Ian W.H.
AU - Smith, David L.
AU - Klein, Eili Y.
N1 - Funding Information:
We are grateful to the World Bank for financial support and to Ian Hastings, Dean Jamison, Phil Musgrove, Mead Over, Robert Ridley and Allan Schapira for comments on an earlier draft.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/5
Y1 - 2010/5
N2 - Malaria kills over a million people each year. The loss of chloroquine due to the spread of parasite resistance is largely responsible for the resurgence of malaria. A new class of antimalarial drugs called artemisinins are available, but are unaffordable to most people in malaria-endemic countries and may quickly face the same fate as chloroquine unless they are combined with a partner drug. Subsidies for artemisinin combination treatments may be warranted on second-best grounds as they deter use of single-ingredient drugs, for which externalities from the risk of resistance evolution are larger. Furthermore, by expanding total effective drug use, subsidies reduce infection transmission externalities among individuals. However, use of combination treatments could still lead to drug resistance and the subsidies themselves entail welfare consequences. This paper develops a conceptual and numerical framework for understanding the conditions under which subsidies for artemisinin combinations can be justified on economic efficiency grounds.
AB - Malaria kills over a million people each year. The loss of chloroquine due to the spread of parasite resistance is largely responsible for the resurgence of malaria. A new class of antimalarial drugs called artemisinins are available, but are unaffordable to most people in malaria-endemic countries and may quickly face the same fate as chloroquine unless they are combined with a partner drug. Subsidies for artemisinin combination treatments may be warranted on second-best grounds as they deter use of single-ingredient drugs, for which externalities from the risk of resistance evolution are larger. Furthermore, by expanding total effective drug use, subsidies reduce infection transmission externalities among individuals. However, use of combination treatments could still lead to drug resistance and the subsidies themselves entail welfare consequences. This paper develops a conceptual and numerical framework for understanding the conditions under which subsidies for artemisinin combinations can be justified on economic efficiency grounds.
KW - Antimalarial drugs
KW - Resistance externality
KW - Subsidies
KW - Transmission externality
KW - Welfare effects
UR - http://www.scopus.com/inward/record.url?scp=77952550458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952550458&partnerID=8YFLogxK
U2 - 10.1016/j.jhealeco.2010.03.002
DO - 10.1016/j.jhealeco.2010.03.002
M3 - Article
C2 - 20381182
AN - SCOPUS:77952550458
SN - 0167-6296
VL - 29
SP - 445
EP - 456
JO - Journal of health economics
JF - Journal of health economics
IS - 3
ER -